ANGN
Angion Biomedica Corp. [ANGN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ANGN Stock Summary
In the News
ANGN Financial details
Company Rating
-
Market Cap
30.11M
Income
-34.19M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
14 Aug 2023
P/E
-0.75
Forward P/E
-
PEG
-0.06
P/S
46.12
P/B
0.76
P/C
-
P/FCF
-0.98
Quick Ratio
19.3
Current Ratio
20
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.24
EPS next Y
-
EPS next Q
-
EPS this Y
-2.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
7.31%
Revenue last 5Y
-10.6%
Revenue Q/Q
-
EPS Q/Q
-47.95%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-96%
ROE
-83%
ROC
-0.75%
Gross Margin
100%
Oper. Margin
-4555%
Profit Margin
-6114%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0-20.4
52W High
-95%
52W Low
0%
RSI
-
Rel Volume
23
Avg Volume
9.77K
Volume
224.8K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
2.04%
-
-
-
-
Beta
0.598413
-
-
Volatility
0.01%, 0.01%
Prev Close
0%
Price
1
Change
-5.66%
Company Profile
- Volume Average 9.77K
- Market Capitalization 30.11M
- Employee 3
- CEO Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.
- Headquarters Uniondale,NY,US
- IPO Date 2021-02-05
-
Website
https://www.angion.com 
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
